--- title: "Adjuvant Large B-Cell Lymphoma Alpha3 | Sutter Health" description: "A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Large B-Cell Lymphoma Alpha3 # Adjuvant Large B-Cell Lymphoma Alpha3 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06500273?term=ALLO-501A-202&rank=1). #### Locations - Berkeley #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. ![Oleg I Krijanovski, M.D., Ph.D.](https://dyn.mktgcdn.com/p/oWPJWgCboUxqZApvrWha8T3bs6ZyRlMgoWXo_AiO4GI/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Oleg I Krijanovski, M.D., Ph.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130) ## Sub-Investigator [Xin Li, M.D., Ph.D.](https://www.sutterhealth.org/research/investigators/xin-li-md-phd-1078064888) ## Email us to enroll - [Email Berkeley](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Large%20B-Cell%20Lymphoma%20Alpha3%20in%20Berkeley&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Lymphoma, Large B-Cell, Diffuse Expanded Access For Subjects Receiving Lisocabtagen Maraleucel JCAR017-EAP-001](https://www.sutterhealth.org/research/clinical-trials/lymphoma-large-b-cell-diffuse-expanded-access-for-subjects-receiving-lisocabtagen-maraleucel-jcar017-eap-001-2062976151) Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release (JCAR017-EAP-001) **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Lymphoma DLBCL waveLINE-010](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-lymphoma-dlbcl-waveline-010-2036971408) A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) MK-2140-010 **Status:** Open to Enrollment - Clinical trial ### [Interventional Myeloma EQUATE EAA181](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964) Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446) Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937) Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release **Status:** Coming Soon [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Large B-Cell Lymphoma Alpha3"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#medicalwebpage","name":"Adjuvant Large B-Cell Lymphoma Alpha3","description":"A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#breadcrumblist"},"mentions":[{"@type":"Person","name":"Oleg I Krijanovski, M.D., Ph.D.","url":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994#medicaltrial","name":"Adjuvant Large B-Cell Lymphoma Alpha3","alternateName":"A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994","description":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.","identifier":"NCT06500273","code":{"@type":"MedicalCode","codeValue":"NCT06500273","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06500273?term=ALLO-501A-202&rank=1","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Lymphoma"},{"@type":"MedicalCondition","name":"Hematologic Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Berkeley"}]} ```